Kai Health Raises Pre-Series A Funding
Kai Health, a Seoul, South Korea-based startup specializing in infertility artificial intelligence (AI) solutions, has secured pre-Series A funding.
Kai Health, a Seoul, South Korea-based startup specializing in infertility artificial intelligence (AI) solutions, has secured pre-Series A funding.
SaaS Investors
The funding round includes investments from IMM Investment, SBVA, Smilegate Investment, and Translink Investment.
Kai Health Use of Funds
The company will use the funding to support the global expansion of its flagship solution, 'Vita Embryo', aimed at increasing the success rates of infertility treatments.
About Kai Health
Founded by Lee Hye-jun, Kai Health has created 'Vita Embryo', an innovative infertility AI solution that enables couples undergoing in vitro fertilization to select the best embryos. The company's platform offers personalized fertility treatment and uses embryo analysis artificial intelligence, helping users to increase pregnancy predictability through objective and accurate embryo analysis and evaluation, reducing costs by improving data collection and work efficiency of medical staff, and creating a healthy family.
Funding Details
Company: Kai Health Co.
Raised: Undisclosed
Round: Pre-Series A
Funding Month: February 2024
Lead Investors:
Additional Investors: IMM Investment, SBVA, Smilegate Investment, and Translink Investment
Company Website: https://www.kaihealth.tech/
Software Category: Infertility AI Solutions
